What is Biohaven's accrued clinical trial costs?

Biohaven (BHVN) reported accrued clinical trial costs of $21.54M in Q1 2026.

How has Biohaven's accrued clinical trial costs changed year-over-year?

Biohaven's accrued clinical trial costs decreased by 32.9% year-over-year, from $32.11M to $21.54M.

Over 4 years (2021 to 2025), Biohaven's accrued clinical trial costs has grown at a 6.1% compound annual growth rate (CAGR), from $24.05M to $30.44M.

Operating income-$130.4M+41.1%

Net income-$130.5M+41.1%

EPS (diluted)-$0.88+59.4%

Cash & equivalents$277.1M+170%

Total debt$286.2M+706%

Total equity$129.5M-50.1%

Total assets$466.4M+1.6%

Operating cash flow-$149.9M+9.2%

CapEx--100%

Free cash flow-$149.9M+9.5%

Market cap$2.25B-48.1%

Enterprise value$2.26B-46.3%

Return on equity-333%+17.9pp

Debt / equity2.2×+2.1×

Current ratio7.4×+5.1×

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept bhvn:AccruedClinicalTrialCostsCurrent.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is Biohaven's accrued clinical trial costs?: Biohaven (BHVN) reported accrued clinical trial costs of $21.54M in Q1 2026.
How has Biohaven's accrued clinical trial costs changed year-over-year?: Biohaven's accrued clinical trial costs decreased by 32.9% year-over-year, from $32.11M to $21.54M.
What is the long-term trend for Biohaven's accrued clinical trial costs?: Over 4 years (2021 to 2025), Biohaven's accrued clinical trial costs has grown at a 6.1% compound annual growth rate (CAGR), from $24.05M to $30.44M.